Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab

Kazuhiro Nouso; Akiko Wakuta; Shohei Shiota; Rio Fujita; Kazuya Kariyama; Atsushi Hiraoka; Masanori Atsukawa; Joji Tani; Toshifumi Tada; Shinichiro Nakamura; Kazuto Tajiri; Masaki Kaibori; Masashi Hirooka; Ei Itobayashi; Satoru Kakizaki; Atsushi Naganuma; Toru Ishikawa; Michitaka Imai; Tomoko Aoki; Hironori Tanaka; Takeshi Hatanaka; Kunihiko Tsuji; Kazuhito Kawata; Koichi Takaguchi; Akemi Tsutsui; Chikara Ogawa; Hironori Ochi; Yutaka Yata; Hidekatsu Kuroda; Tomomitsu Matono; Satoshi Yasuda; Hidenori Toyoda; Hiroko Iijima; Masatoshi Kudo; Takashi Kumada

doi:10.1002/jgh3.70346

Key Points

No notable impact of butyrate-producing bacteria on the efficacy of immune checkpoint inhibitors.
Proton pump inhibitor use did not significantly change treatment outcomes with durvalumab and tremelimumab.
The study indicates that the liver's immunotolerant environment may constrain microbiome modulation effects.
These findings highlight potential challenges in enhancing cancer treatment efficacy through microbiome interventions.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis shows no significant effect on treatment efficacy in hepatocellular carcinoma, suggesting limited microbiome influence.

Abstract

Neither butyrate-producing bacteria nor PPI use significantly influenced the efficacy of durvalumab plus tremelimumab in HCC. The liver's immunotolerant microenvironment may limit the impact of microbiome modulation on ICI efficacy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nouso et al. (2026) studied this question.

synapsesocial.com/papers/69a75b18c6e9836116a21c82 https://doi.org/10.1002/jgh3.70346

View Full Paper

Ask AI

Bookmark

Share

Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading